PMID- 35399507
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 10
DP  - 2022
TI  - The Impact of Metabolic Syndrome and Type 2 Diabetes Mellitus on Prostate Cancer.
PG  - 843458
LID - 10.3389/fcell.2022.843458 [doi]
LID - 843458
AB  - Prostate cancer (PCa) remains the second most common type of cancer in men 
      worldwide in 2020. Despite its low death rate, the need for new therapies or 
      prevention strategies is critical. The prostate carcinogenesis process is complex 
      and multifactorial. PCa is caused by a variety of mutations and carcinogenic 
      events that constitutes the disease's multifactorial focus, capable of not only 
      remodeling cellular activity, but also modeling metabolic pathways to allow 
      adaptation to the nutritional requirements of the tumor, creating a propitious 
      microenvironment. Some risk factors have been linked to the development of PCa, 
      including Metabolic Syndrome (MetS) and Type 2 Diabetes Mellitus (T2DM). MetS is 
      intrinsically related to PCa carcinogenic development, increasing its 
      aggressiveness. On the other hand, T2DM has the opposite impact, although in 
      other carcinomas its effect is similar to the MetS. Although these two metabolic 
      disorders may share some developmental processes, such as obesity, insulin 
      resistance, and dyslipidemia, their influence on PCa prognosis appears to have an 
      inverse effect, which makes this a paradox. Understanding the phenomena behind 
      this paradoxical behavior may lead to new concepts into the comprehension of the 
      diseases, as well as to evaluate new therapeutical targets. Thus, this review 
      aimed to evaluate the impact of metabolic disorders in PCa's aggressiveness state 
      and metabolism.
CI  - Copyright (c) 2022 Sousa, Costa, Alves, Soares, Baylina and Fernandes.
FAU - Sousa, Andre P
AU  - Sousa AP
AD  - LaBMI-Laboratorio de Biotecnologia Medica e Industrial, Porto, Portugal.
AD  - Department of Biomedicine, Unit of Biochemistry, Faculty of Medicine of Porto 
      University, Porto, Portugal.
AD  - I3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal.
AD  - ESS-Escola Superior de Saude, Instituto Politecnico do Porto, Porto, Portugal.
FAU - Costa, Raquel
AU  - Costa R
AD  - LaBMI-Laboratorio de Biotecnologia Medica e Industrial, Porto, Portugal.
AD  - Department of Biomedicine, Unit of Biochemistry, Faculty of Medicine of Porto 
      University, Porto, Portugal.
AD  - I3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal.
FAU - Alves, Marco G
AU  - Alves MG
AD  - ICBAS-Instituto de Ciencias Biomedicas Abel Salazar, Porto, Portugal.
FAU - Soares, Raquel
AU  - Soares R
AD  - Department of Biomedicine, Unit of Biochemistry, Faculty of Medicine of Porto 
      University, Porto, Portugal.
AD  - I3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal.
FAU - Baylina, Pilar
AU  - Baylina P
AD  - LaBMI-Laboratorio de Biotecnologia Medica e Industrial, Porto, Portugal.
AD  - I3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal.
AD  - ESS-Escola Superior de Saude, Instituto Politecnico do Porto, Porto, Portugal.
FAU - Fernandes, Ruben
AU  - Fernandes R
AD  - LaBMI-Laboratorio de Biotecnologia Medica e Industrial, Porto, Portugal.
AD  - I3S-Instituto de Investigacao e Inovacao em Saude, Porto, Portugal.
AD  - ESS-Escola Superior de Saude, Instituto Politecnico do Porto, Porto, Portugal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220325
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC8992047
OTO - NOTNLM
OT  - cancer biology
OT  - diabetes
OT  - metabolic syndrome
OT  - metabolism
OT  - prostate cancer
OT  - signaling/signaling pathways
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/01/01
CRDT- 2022/04/11 05:14
PHST- 2021/12/25 00:00 [received]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/04/11 05:14 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 843458 [pii]
AID - 10.3389/fcell.2022.843458 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2022 Mar 25;10:843458. doi: 10.3389/fcell.2022.843458. 
      eCollection 2022.